Abstract:Objective: To investigate the levels of interleukin-1β (IL-1β) and tumor necrosis factor α (TNF-α) in both serum and CSF in patients with Alzheimer disease. Methods: Eleven patients with Alzheimer disease, 13 patients with vascular dementia (VD) and 13 healthy controls were analyzed by using commercial ELISA kits. Results: The average serum level of IL-1β was found higher in AD patients(60.13 ± 17.81 pg/ml) than in VD patients(38.51 ± 14.39 pg/ml) and in healthy controls (33.98 ± 16.31 pg/ml) (P < 0.01, respectively). Though the serum TNF-α level was slightly higher in AD patients(81.20 ± 23.99 pg/ml) than in VD patients(71.77 ± 28.86 pg/ml) or healthy controls (73.91 ± 17.69 pg/ml), none reached at a statistical significance. CSF IL-1β levels were found elevated in AD patients (38.25 ± 18.42 pg/ml) as compared to the healthy controls(20.25 ± 15.86 pg/ml) and VD patients(32.18 ± 19.81 pg/ml) (P < 0.05, respectively). AD patients were found to have higher CSF TNF-α levels(142.58 ± 11.46 pg/ml) than VD patients(115.46 ± 19.52 pg/ml)and controls(106.23 ± 26.13 pg/ml) (P < 0.05 and P < 0.01, respectively). Conclusion: These results strongly suggest that inflammatory cytokines IL-1β and TNF-α should be important factors in the neurodegeneration process associated with AD and the inflammation should significantly contribute to the pathogenesis of AD. Specific therapeutic strategies aimed at modulation of cytokines network in AD would have considerable promise.

Detection of interleukin-1β and tumor necrosis factor α in serum and cerebrospinal fluid in patients with Alzheimer disease